XVIVO Perfusion adds two more XPS™ installations in the U.S.

The two XPS™ now ordered are the first for a transplant center in California and
the first for a transplant center in Virginia. It is estimated that delivery of
XPS™ to these two centers will take place in August. The number of centers in
the United States that have access to an XPS™ for performing Ex-Vivo Lung
Perfusion will now increase to 18.
California has the highest population count of all states in the US and is
ranked among the top five regarding the number of lung transplants performed in
the US. Virginia is the twelfth most populated state in the US and has seen a
growing number of lung transplants in the recent years.

"We are looking forward to working with XVIVO to advance the success of lung
transplantation at UVA by combining our excellent outcomes with innovative
technology to increase the number of available lungs to patients on our
transplant list" says Christine Lau, MD, Associate Professor of Surgery, Univ.
of Virginia.

“The lung transplant program at Cedars-Sinai Medical Center in Los Angeles is
very excited and eager to begin participation in XVIVO’s ex-vivo lung perfusion
system protocol. Each year hundreds of potentially transplantable lungs from
extended criteria donors nationwide are needlessly wasted due to marginal
quality thus increasing the waiting time for patients on the lung transplant
wait list and increasing their risk of death while waiting. With the use of EVLP
we hope to broaden the donor pool for our wait-listed patients so that they can
receive a lifesaving lung transplant before it becomes too late for them”, says
George E. Chaux, Medical Director, Lung and Heart-Lung Transplant Program,
Cedars-Sinai Medical Center.

XVIVO Perfusion’s XPS™ and STEEN Solution™ are the only approved products in the
USA for evaluation of marginal lungs before lung transplantation. The products
enable more lungs to be used for transplantation, which means that more patients
with severe lung disease are given a higher quality and longer life. Leading
clinics in the USA have obtained good clinical results when using XPS™.

August 3, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on August 3, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com